Aricept contains donepezil, a cholinesterase inhibitor used to manage symptoms associated with Alzheimer’s disease and some dementia syndromes. It is prescribed for adults with cognitive decline, helping preserve acetylcholine activity in the brain and support memory, attention, and daily functioning.
Aricept is the brand name associated with donepezil, an oral tablet used in the symptomatic treatment of Alzheimer’s disease. Alzheimer’s disease is the most common cause of dementia, a broader term covering problems with memory, reasoning, communication, behaviour, and everyday independence.
Donepezil may help some people maintain cognitive and functional abilities for a period of time. The response varies between individuals. Treatment is usually assessed through changes in memory, orientation, conversation, behaviour, and the ability to complete familiar tasks rather than through one laboratory test.
Eisai Inc. developed donepezil as a centrally acting cholinesterase inhibitor. The medicine is used within a wider care plan that may also include support for sleep, nutrition, mobility, communication, and carer wellbeing.
The active ingredient is donepezil. It belongs to the cholinesterase inhibitor class.
Cholinesterase inhibitors reduce the breakdown of acetylcholine, a neurotransmitter involved in memory and learning. Aricept tablets are taken by mouth, and treatment is generally continued while the person gains a worthwhile clinical benefit and tolerates the medicine.
An important practical detail is that a person may not feel a dramatic change after starting Aricept. The goal is often slower loss of function, better engagement, or more stable daily performance rather than a sudden improvement in memory.
Aricept is the brand name associated with donepezil, an oral tablet used in the symptomatic treatment of Alzheimer’s disease.
Donepezil may help some people maintain cognitive and functional abilities for a period of time. The medicine is used within a wider care plan that may also include support for sleep, nutrition, mobility, communication, and carer wellbeing.
Donepezil inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine in the spaces between nerve cells. This leaves more acetylcholine available for communication between neurons.
In Alzheimer’s disease, cholinergic nerve pathways become impaired. By preserving acetylcholine activity, donepezil can support the signalling involved in attention, learning, and memory. It does not remove amyloid plaques or neurofibrillary tangles, and it does not stop the biological process that causes Alzheimer’s disease.
The medicine has a different mechanism from antidepressants and from medicines that target brain inflammation or amyloid proteins. Its action is symptomatic: it supports a neurotransmitter system that remains active despite progressive nerve-cell damage.
The European Medicines Agency describes donepezil as a centrally acting acetylcholinesterase inhibitor [1].
Medicines that slow the heart rate can add to donepezil’s effect and may increase the risk of dizziness, fainting, or conduction problems. Examples include some beta-blockers, certain calcium-channel blockers, and medicines used for abnormal heart rhythms.
Non-steroidal anti-inflammatory drugs can increase the risk of gastrointestinal irritation or bleeding, especially in an older person with a history of ulcers. Anticholinergic medicines can oppose the action of donepezil and may reduce its benefit. Some medicines that inhibit or induce liver enzymes can alter donepezil exposure.
Tell the prescriber before surgery because anaesthetic medicines, including some neuromuscular-blocking agents, may interact with cholinesterase inhibitors. A history of slow pulse, peptic ulcer, asthma, seizures, urinary obstruction, or severe liver impairment deserves specific review.
Aricept is not suitable for everyone. A prescriber should review the person’s medical history and medicines before treatment begins.
This medication is not for you if:
Donepezil can increase cholinergic activity in the digestive system and other organs. The side effects most often associated with treatment include nausea, vomiting, diarrhoea, abdominal discomfort, reduced appetite, headache, dizziness, muscle cramps, insomnia, and unusual dreams. These effects are often more noticeable after treatment starts or after an increase in dose.
Common effects may improve as the body adapts. Taking the tablet consistently and maintaining fluid intake can help with mild gastrointestinal symptoms, provided the person has no fluid restriction. Persistent vomiting or diarrhoea needs attention because dehydration can worsen dizziness, confusion, kidney function, and the risk of falls.
| Adverse effect | Practical significance |
|---|---|
| Nausea, vomiting, diarrhoea | May cause dehydration, appetite loss, or weight reduction |
| Insomnia or vivid dreams | Can disturb sleep; dosing time may need review |
| Dizziness or faintness | May increase falls risk, especially in older adults |
| Slow pulse or palpitations | Requires prompt clinical assessment if accompanied by weakness or fainting |
Serious reactions are less common but need urgent assessment. These include fainting, a very slow heartbeat, chest pain, seizures, black stools, vomiting blood, severe abdominal pain, breathing difficulty, facial swelling, or a widespread blistering rash.
A useful detail for carers is that appetite loss may be gradual. Clothes becoming looser, reduced interest in meals, or leaving more food untouched can be easier to notice than a stated complaint of nausea. Weight and hydration are worth discussing during treatment reviews.
The active ingredient is donepezil. It belongs to the cholinesterase inhibitor class.
The amount of Aricept used and how often it is taken depend on the purpose of treatment and are agreed with a doctor or pharmacist. For Alzheimer’s disease, clinicians commonly begin with a lower daily dose and may increase it after assessing tolerability and response.
Practical administration points include:
Aricept is usually continued for as long as the person shows meaningful benefit and tolerates treatment. A clinician may review cognition, daily activities, adverse effects, weight, pulse, and carer observations during follow-up.
Tablets should not be crushed or chewed unless a clinician or pharmacist has specifically confirmed that this is suitable for the prescribed product. Altering a tablet can make swallowing harder, create an unpleasant taste, or interfere with the intended way the dose is released.
Donepezil, rivastigmine, and galantamine all belong to the cholinesterase inhibitor class. They share a broad treatment aim but differ in formulation, metabolism, dosing arrangements, and tolerability.
| Medicine | Main pharmacological feature | Common practical distinction |
|---|---|---|
| Donepezil | Inhibits acetylcholinesterase | Oral treatment with a long duration of action |
| Rivastigmine | Inhibits acetylcholinesterase and butyrylcholinesterase | Available as oral treatment and a transdermal patch |
| Galantamine | Inhibits acetylcholinesterase and modulates nicotinic receptors | Oral treatment with formulation-dependent dosing |
A clinician may consider rivastigmine when swallowing tablets is difficult or when a patch could support a steadier administration routine. Skin irritation is a limitation of the patch, and application sites must be rotated.
Galantamine may be selected when its formulation and dosing pattern suit the person’s routine. Digestive effects can occur with it as well. Donepezil may be preferred when once-daily oral treatment fits the care plan, though sleep disturbance, gastrointestinal symptoms, or a slow pulse may lead to a review.
The choice is not based on memory scores alone. Prescribers also consider frailty, falls, heart rhythm, swallowing ability, kidney and liver function, other medicines, and the practical support available at home. NICE recommends cholinesterase inhibitors for appropriate stages of Alzheimer’s disease after an individual clinical assessment [2].
Several practical mistakes can reduce benefit or increase harm:
One easily missed issue is the difference between disease progression and an acute medical problem. Sudden confusion, a rapid decline, fever, pain, dehydration, or a new fall may indicate infection, medication toxicity, or another urgent condition rather than ordinary Alzheimer’s progression.
In clinical practice, doctors often judge Aricept by function rather than by a promise of restored memory. A person who remains able to follow a conversation, manage personal care, or participate in familiar activities may be receiving meaningful benefit even when memory testing continues to worsen.
Treatment reviews usually include the patient, a family member, or a carer because cognitive changes can be difficult for the patient to recognise. Pulse, weight, appetite, falls, sleep, bowel symptoms, and adherence also matter.
The medicine works best as part of an organised care plan. Doses taken irregularly can make benefit difficult to judge, while an unnoticed appetite decline can create a separate health problem. Clinicians may stop treatment when adverse effects outweigh benefit, when the disease has progressed to a stage where there is no observable value, or when the person’s care goals change.
Aricept can interact with medicines that slow the heart, increase stomach irritation, or oppose cholinergic activity. This includes some beta-blockers, certain heart-rhythm medicines, non-steroidal anti-inflammatory drugs, and anticholinergic products used for bladder symptoms, sleep, allergies, or travel sickness. The 2018 MHRA safety information for donepezil and related medicines supports reviewing the full medication list before treatment changes [3]. Herbal supplements should also be disclosed. Their ingredients and effects vary.
A serious allergy to donepezil or a previous severe reaction to a related compound rules out treatment. Significant untreated bradycardia, certain conduction disorders, active peptic ulcer disease, uncontrolled seizures, severe asthma, and severe liver impairment may also make treatment unsuitable. The 2018 NICE guidance supports individual assessment before a cholinesterase inhibitor is started. A past stomach ulcer or fainting episode does not automatically end treatment, but it requires a specific clinical review.
Aricept is not routinely used in children or adolescents. The evidence base and regulatory use concern adults with Alzheimer’s disease, rather than ordinary concentration problems or childhood memory difficulties. The 2018 EMA product information describes adult use and does not establish routine paediatric treatment. A specialist would need to assess any unusual younger-person situation separately instead of applying an adult dementia regimen.
Urgent assessment is needed for fainting, severe weakness with a slow pulse, chest pain, breathing difficulty, facial swelling, seizures, vomiting blood, black stools, severe abdominal pain, or a widespread blistering rash. These symptoms can indicate a cardiovascular, gastrointestinal, neurological, or allergic complication. The 2019 FDA prescribing information for donepezil includes warnings about bradycardia, gastrointestinal effects, seizures, and serious hypersensitivity reactions. Do not take another dose after a severe reaction until urgent medical advice has been obtained.
The best time is the time that supports regular daily use and produces the fewest troublesome effects. Evening dosing is common, yet morning dosing may be considered when vivid dreams or insomnia occur. The 2018 EMA product information describes once-daily administration, with the schedule adjusted clinically when tolerability is a problem. Changing the time can help some patients, but the prescribed daily amount should not be changed at the same time without medical direction.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Dundee, reported taking Aricept at the prescribed daily dose for several months under a memory-clinic plan. His family noticed that he followed conversations for longer and missed fewer familiar steps in his morning routine. Early nausea reduced his appetite for about two weeks, so his weight was monitored closely.
Reading, described a mixed response after taking the prescribed daily dose for several months for early-onset Alzheimer’s disease. Concentration during short conversations seemed better, but vivid dreams and poor sleep became troublesome when the tablet was taken late at night. A clinician reviewed the timing and other medicines rather than increasing the dose immediately.
Wolverhampton, said that Aricept had not produced a dramatic memory improvement during the first several months at the prescribed daily dose. He still found the treatment worthwhile because his relative remained more engaged with meals and simple household tasks, although occasional diarrhoea made hydration a daily concern.
